Resources

In clinics and communities, thousands of health workers have been trained to safely administer the self-injectable contraceptive subcutaneous DMPA (DMPA-SC)—including support for women learning to self-inject. Visit the DMPA-SC Resource Library to access training and supportive supervision materials to equip facility- and community-based family planning providers in the public and private sector.For more information, contact FPoptions@path.org or sign up for our newsletters.

Since 2016, PATH has been supporting the implementation of the U.S. President's Emergency Plan for AIDS Relief's DREAMS programming to keep AGYW HIV-free with a holistic package of health, economic empowerment, education, and social services. After DREAMS enrollees receive all of their age-specific services, they graduate and exit the project. Despite having participated in financial capability and entrepreneurship training, many young women still lack the networks, opportunities, and capital to earn a living and become financially stable.The PATH-led Chak a Chaka project provides DREAMS graduates with opportunities to save, build, and employ entrepreneurial skills and create supportive and sustainable networks that protect their health and wellbeing, and that of their children and families. This factsheet provides additional details on the Chak a Chaka project and its successes to date.

PATH has been contributing to Myanmar’s healthcare transformation since 2012 and supports the government’s commitment to achieve universal health coverage by 2030. PATH works with government, non-governmental actors, and private sector to leverage partnerships, policy advocacy, new technologies, and innovative approaches to address inequities in key health areas – nutrition, vaccines and immunization, sexual and reproductive health, infectious diseases, and non-communicable diseases.This factsheet talks about the various completed and ongoing projects under family health.

A synthesis of the full review on current, published evidence relevant to single-dose HPV vaccination. This includes immunogenicity, efficacy and effectiveness; identification of gaps in the evidence; and forthcoming evidence. Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

The primary objective of this review is to summarize and assess the current evidence that could support a change to a single-dose schedule of HPV vaccine. The review also aims to identify gaps that remain in determining whether a single dose could be sufficiently protective to have a major impact against HPV infection and its sequelae, within the context of immunization programs. See also the companion resources:General summary (five pages)Technical synthesis (30 pages), of immunogenicity, efficacy, and effectiveness, forthcoming evidence, and areas for future research.Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.